This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignees: National Institute of Health and Medical Research, American University of Beirut, Assistance Publique - Hopitaux De Paris (Aphp). Active years: 2020-2021.
Company Filing History:
2 out of 1,853 
1 out of 27 
1 out of 77 
Years Active: 2020-2021
Title: The Innovations of Peter Lenting
Introduction
Peter Lenting is a notable inventor based in Le Kremlin-Bicetre, France. He has made significant contributions to the field of medical research, particularly in the treatment of haemophilia. With a total of 2 patents to his name, Lenting's work has the potential to impact many lives.
Latest Patents
Lenting's latest patents focus on mutated factor X polypeptides and their applications in treating haemophilia. The first patent describes a mutated factor X (FX) polypeptide that includes a heavy chain with at least one amino acid residue mutated at position 401 or 408. The second patent also pertains to mutated factor X polypeptides, specifically highlighting a heavy chain with mutations at position 441 and/or 448 of SEQ ID NO: 1. These innovations represent a significant advancement in the therapeutic approaches to managing haemophilia.
Career Highlights
Throughout his career, Peter Lenting has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université Paris—Sud. His research has been pivotal in advancing our understanding of haemophilia and developing new treatment options.
Collaborations
Lenting has collaborated with notable colleagues, including Olivier Christophe and Cecile Denis. These partnerships have contributed to the success of his research and the development of his patents.
Conclusion
Peter Lenting's contributions to the field of medical research, particularly in haemophilia treatment, are commendable. His innovative patents and collaborations highlight his dedication to improving healthcare outcomes.